Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

BAP1, a tumor suppressor gene driving malignant mesothelioma.

Cheung M, Testa JR.

Transl Lung Cancer Res. 2017 Jun;6(3):270-278. doi: 10.21037/tlcr.2017.05.03. Review.

2.

Mesothelioma: recent highlights.

Carbone M, Yang H.

Ann Transl Med. 2017 Jun;5(11):238. doi: 10.21037/atm.2017.04.29. Review.

3.

SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma.

Pópulo H, Batista R, Sampaio C, Pardal J, Lopes JM, Soares P.

PLoS One. 2017 Jun 29;12(6):e0180392. doi: 10.1371/journal.pone.0180392. eCollection 2017.

4.

Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.

Kageyama K, Ohara M, Saito K, Ozaki S, Terai M, Mastrangelo MJ, Fortina P, Aplin AE, Sato T.

J Transl Med. 2017 Jun 23;15(1):145. doi: 10.1186/s12967-017-1247-z.

5.

Systematic genomic and translational efficiency studies of uveal melanoma.

Johnson CP, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Lane AM, Gragoudas ES, Vazquez F, Nickerson E, Cibulskis K, McKenna A, Gabriel SB, Getz G, Van Allen EM, 't Hoen PAC, Garraway LA, Woodman SE.

PLoS One. 2017 Jun 8;12(6):e0178189. doi: 10.1371/journal.pone.0178189. eCollection 2017.

6.

Atypical Presentation: Metastatic Uveal Melanoma in a Young Patient without Visual Complaints.

Buiar PG, de Azevedo SJ.

Front Oncol. 2017 May 18;7:99. doi: 10.3389/fonc.2017.00099. eCollection 2017.

7.

Ubiquitination in melanoma pathogenesis and treatment.

Ma J, Guo W, Li C.

Cancer Med. 2017 Jun;6(6):1362-1377. doi: 10.1002/cam4.1069. Epub 2017 May 23. Review.

8.

Focus on cutaneous and uveal melanoma specificities.

Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C.

Genes Dev. 2017 Apr 15;31(8):724-743. doi: 10.1101/gad.296962.117. Review.

PMID:
28512236
9.

Brachytherapy and anterior segment imaging in iris melanoma.

Song JSA, Dmytriw AA, Lakosha H.

Ecancermedicalscience. 2017 Apr 18;11:734. doi: 10.3332/ecancer.2017.734. eCollection 2017.

10.

Loss of nuclear BAP1 expression is associated with poor prognosis in oral mucosal melanoma.

Song H, Wang L, Lyu J, Wu Y, Guo W, Ren G.

Oncotarget. 2017 Apr 25;8(17):29080-29090. doi: 10.18632/oncotarget.16175.

11.

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.

Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, Sabesan AC, Srivastava AK, Xi L, Pham TH, Raffeld M, White DE, Toomey MA, Rosenberg SA, Kammula US.

Lancet Oncol. 2017 Jun;18(6):792-802. doi: 10.1016/S1470-2045(17)30251-6. Epub 2017 Apr 7.

PMID:
28395880
12.

Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.

Gezgin G, Dogrusöz M, van Essen TH, Kroes WGM, Luyten GPM, van der Velden PA, Walter V, Verdijk RM, van Hall T, van der Burg SH, Jager MJ.

Cancer Immunol Immunother. 2017 Jul;66(7):903-912. doi: 10.1007/s00262-017-1991-1. Epub 2017 Apr 8.

13.

CANT1 lncRNA Triggers Efficient Therapeutic Efficacy by Correcting Aberrant lncing Cascade in Malignant Uveal Melanoma.

Xing Y, Wen X, Ding X, Fan J, Chai P, Jia R, Ge S, Qian G, Zhang H, Fan X.

Mol Ther. 2017 May 3;25(5):1209-1221. doi: 10.1016/j.ymthe.2017.02.016. Epub 2017 Mar 18.

PMID:
28330694
14.

Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report.

Bhangoo MS, Zhou JY, Ali SM, Madison R, Schrock AB, Costantini C.

BMC Cancer. 2017 Mar 16;17(1):197. doi: 10.1186/s12885-017-3167-y.

15.

Identification, genetic testing, and management of hereditary melanoma.

Leachman SA, Lucero OM, Sampson JE, Cassidy P, Bruno W, Queirolo P, Ghiorzo P.

Cancer Metastasis Rev. 2017 Mar;36(1):77-90. doi: 10.1007/s10555-017-9661-5.

16.

The biology of uveal melanoma.

Amaro A, Gangemi R, Piaggio F, Angelini G, Barisione G, Ferrini S, Pfeffer U.

Cancer Metastasis Rev. 2017 Mar;36(1):109-140. doi: 10.1007/s10555-017-9663-3.

17.

Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.

Chua V, Lapadula D, Randolph C, Benovic JL, Wedegaertner PB, Aplin AE.

Mol Cancer Res. 2017 May;15(5):501-506. doi: 10.1158/1541-7786.MCR-17-0007. Epub 2017 Feb 21. Review.

PMID:
28223438
18.

Uveal melanoma: epidemiology, etiology, and treatment of primary disease.

Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD.

Clin Ophthalmol. 2017 Jan 31;11:279-289. doi: 10.2147/OPTH.S89591. eCollection 2017. Review.

19.

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.

Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T, Aplin AE.

Mol Cancer Ther. 2017 Mar;16(3):516-528. doi: 10.1158/1535-7163.MCT-16-0552. Epub 2017 Jan 30.

PMID:
28138035
20.

The Long Non-Coding RNA RHPN1-AS1 Promotes Uveal Melanoma Progression.

Lu L, Yu X, Zhang L, Ding X, Pan H, Wen X, Xu S, Xing Y, Fan J, Ge S, Zhang H, Jia R, Fan X.

Int J Mol Sci. 2017 Jan 23;18(1). pii: E226. doi: 10.3390/ijms18010226.

Supplemental Content

Support Center